2017 American Transplant Congress
Systemic Meta-Analysis: Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients?
Aim: This meta-analysis focuses on the current evidence of renal graft functioning and graft survival following early conversion to mTOR inhibitors with or without CNI…2017 American Transplant Congress
Conversion from Calcineurin Inhibitor to Sirolimus in Kidney Transplantation Recipients with Malignancy.
Nephrology, Asan Medical Center, Seoul, Republic of Korea
Background: Kidney transplant recipients are at an increased risk of malignancy for various reasons, such as the chronic use of calcineurin inhibitor (CNI). Sirolimus (SRL),…2017 American Transplant Congress
Efficacy of Calcineurin Inhibitors Transferring to Rapamycin in Live Kidney Transplantation from Old Donors to Young Recipients.
Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Background Calcineurin inhibitor(CNI) nephrotoxicity is one of the major reasons for chronic allograft injury in live kidney transplantation from old donors to young recipients. Therefore…2017 American Transplant Congress
Influence of Tacrolimus Metabolism Rate on Patients' Survival After Renal Transplantation.
Introduction: Tacrolimus (Tac) is an integral part of the immunosuppressive regimen after renal transplantation (RTx). A fast Tac metabolism rate defined as the Tac blood…2017 American Transplant Congress
Tacrolimus Appears to Be a Protective Factor for De Novo DSA Formation in Non-Sensitized Kidney Transplant Patients.
Background.Development of de novo donor specific antibodies (dnDSA) concerns about 10% of patients within the first year following kidney transplantation and reach about 20% within…2017 American Transplant Congress
Early Exposure of Everolimus with and without Calcineurin Inhibitors.
Nephrology Division, Hospital do Rim, UNIFESP, São Paulo, SP, Brazil
This study aimed to evaluate the effect of cyclosporine (CSA) or tacrolimus (TAC) on early exposure of everolimus (EVR).A cohort of 306 kidney transplant recipients…2016 American Transplant Congress
Everolimus and Low Dose Cyclosporine Immunosuppressive Regimen and Development of Anti HLA Donor Specific Antibodies.
Few data are available on the rate of de novo anti-HLA donor specific antibodies (DSA) with the use of everolimus in kidney transplant recipients.MaterialsWe selected…2016 American Transplant Congress
Calcineurin Inhibitor (CNI) Delay with ATG Induction: Teaching an Old Dog, New Tricks.
CNI delay early after heart transplantation is a recommended therapeutic option according to ISHLT guidelines. However, there exist only few published data on feasibility of…2016 American Transplant Congress
Pharmakokinetics of Prolonged-Release Formulation of Tacrolimus: Comparison of AUC0-24 and Concentration at 10 Time Points.
Background:Use of an appropriate immunosuppressant is necessary for good graft survival in kidney transplantation (KTx). Currently, a prolonged-release formulation of tacrolimus (Graceptor or Adovagraf, Astellas…2016 American Transplant Congress
Calcineurin Inhibitor (CNI) Nephrotoxicity Is Mediated by Defective Amp-Activated Protein Kinase (AMPK) Activation.
Medicine, UAB, Birmingham, AL.
Background: CNIs are potent immunosuppressant therapies, but associated with nephrotoxicity manifested by interstitial fibrosis and progressive graft dysfunction. AMPK is a major sensor and regulator…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 16
- Next Page »